Sunrest Lifescience Ltd
Incorporated in 2017, Sunrest Lifescience Ltd trades in Health care and Cosmetics products[1]
- Market Cap ₹ 29.2 Cr.
- Current Price ₹ 34.0
- High / Low ₹ 54.4 / 26.4
- Stock P/E 7.08
- Book Value ₹ 23.8
- Dividend Yield 0.00 %
- ROCE 28.6 %
- ROE 22.4 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 282 to 167 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 167 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 33.41 | 70.83 | |
| 30.38 | 60.62 | |
| Operating Profit | 3.03 | 10.21 |
| OPM % | 9.07% | 14.41% |
| 0.00 | 2.51 | |
| Interest | 0.31 | 1.42 |
| Depreciation | 0.10 | 1.19 |
| Profit before tax | 2.62 | 10.11 |
| Tax % | 23.28% | 20.87% |
| 2.02 | 8.00 | |
| EPS in Rs | 2.34 | 4.80 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 112% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 105% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 22% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 4.29 | 4.29 |
| Reserves | 12.02 | 16.14 |
| 12.05 | 17.46 | |
| 30.29 | 33.52 | |
| Total Liabilities | 58.65 | 71.41 |
| 4.36 | 8.55 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 |
| 54.29 | 62.86 | |
| Total Assets | 58.65 | 71.41 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 2.92 | -0.05 | |
| -1.15 | -2.91 | |
| -0.33 | 3.99 | |
| Net Cash Flow | 1.45 | 1.03 |
| Free Cash Flow | 1.76 | -2.76 |
| CFO/OP | 112% | 14% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 397.34 | 167.27 |
| Inventory Days | 174.78 | 140.69 |
| Days Payable | 416.60 | 173.35 |
| Cash Conversion Cycle | 155.52 | 134.62 |
| Working Capital Days | 228.33 | 155.88 |
| ROCE % | 28.55% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Trade Receivable Turnover Ratio Times ・Standalone data |
|
||
| Medical Representatives (MR) Reimbursement Expense INR Lakhs ・Standalone data |
|||
| Number of Employees Number ・Standalone data |
|||
| Number of Subsidiaries Number ・Standalone data |
|||
Extracted by Screener AI
Documents
Announcements
-
Updates
29 May 2026 - Sunrest Lifescience says Annual Secretarial Compliance Report under Regulation 24A is not applicable as an SME-listed company.
-
Updates
29 May 2026 - Confirmed non-applicability of SEBI large corporate debt-raising circular as of 31 March 2026.
-
Outcome of Board Meeting
29 May 2026 - Board approved FY26 audited standalone and consolidated results, appointed VRCA & Associates, and received unmodified audit opinion.
-
Disclosure under SEBI Takeover Regulations
18 May 2026 - Sunrest Lifescience Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …
-
General Updates
14 May 2026 - Board reconstituted Audit Committee and Stakeholders Relationship Committee effective 14 May 2026.
Business Overview:[1][2]
SLSL is in the business of trading of Pharmaceutical Product on wholesale and retail basis. It provides OTC brands in healthcare & personal care viz. Capsules, Tablets, Syrup, Ointment, Gel, mouthwash, Solution, Suspension, Dry Powders, and Toothpaste